RxDoctor Payments Data

Catherine Schwender, MD

Urology · Watkinsville, GANPI 1174628127

Payments from drug & device makers

$5,500in general payments, 2019–2025

Across 232 payments — averaging $23.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$808
  • Astellas Pharma US Inc$750
  • AbbVie$453
  • Bayer$437
  • Johnson & Johnson$418
  • Ferring Pharmaceuticals Inc.$278
  • plus $2K from 38 others

What the payments were for

  • Travel & lodging$2474%
  • Food & beverage$4,93690%
  • Education$3166%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,500 in reported general payments places this provider in the 55th percentile of 369 urology providers in Georgia.

See all urology providers in Georgia

Medicare billing

Part B allowed, 2024
$575,187
Medicare patients
876
Services billed
14,860

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron282$213,891
XtandiEnzalutamide13$181,028
GemtesaVibegron209$150,751
OrgovyxRelugolix32$85,351
Estradiol162$14,685
Methenamine Hippurate196$13,161
Darifenacin ErDarifenacin Hydrobromide37$9,901
Testosterone33$7,809
Fosfomycin Tromethamine13$5,460
YuvafemEstradiol25$4,011
Solifenacin Succinate107$3,857
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst176$3,625
Oxybutynin Chloride ErOxybutynin Chloride196$3,520
Trospium Chloride ErTrospium Chloride20$3,204
NitrofurantoinNitrofurantoin Macrocrystal101$2,900

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq, Xtandi$750$394,919295 claims
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$45$236,102241 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 369 urology providers in Georgia.

Other urology in Watkinsville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →